JW0104+C2402

Phase 3Small molecule

JJW Pharmaceutical

JW0104+C2402 is one of 34 small molecule programs targeting Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypertensionRecruiting

HypertensionPhase 3

Recruiting

Competition

Competitive Landscape

157 competitors in Hypertension

#DrugCompanyPhaseTrials

Foundayo

Eli Lilly

Phase 3

3 2

Baxfendy

AstraZeneca

Phase 3

3 3

Nitrostat

VViatris Specialty LLC

Phase 3

5 4

Alka-Seltzer

AAbbott

Phase 3

1 5

JW0104+C2402

JJW Pharmaceutical

Phase 3

1 6

HCP1803-3

Hanmi Pharmaceutical Company Limited

Phase 3

1 7

SGLT2

PProf. Dr. med. Ingo Eitel

Phase 3

1 8

Avastin

Roche

Preclinical

1 9

Winrevair

Alphagan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypertension1 trial

Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

Recruiting·JJW Pharmaceutical·Phase 3·NCT06643130·162 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JW0104+C2402. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JW0104+C2402 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JW0104+C2402. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — JW Pharmaceutical company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJW Pharmaceutical

JW0104+C2402

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypertension1 trial

References

Drug Info

Quick Facts

Related News